Auspex Pharmaceuticals Inc

Auspex Pharmaceuticals — Investor Presentation (December 2014)

15 slides from Auspex Pharmaceuticals's investor presentation, Dec 16, 2014

  1. Slide 1: Treating Movement Disorders

    Exhibit 99.1 Treating Movement Huntington’s 1DECEMBER Tardive 16, 2014 Disorders Tourette Disease Dyskinesia Syndrome

  2. Slide 2: Forward-Looking Statements

    Forward Statements are Auspex’s product requirements candidates; conduct significant parties expected; delay and This forecasts may All uncertainties. Securities December subject forward-looking Auspex’s differ presentation orwith candidates. additional prevent Looking prepared ability Auspex’s and

  3. Slide 3: Huntington's Disease Overview

    Overview Progressive, and Movement Behavioral Chorea: 90% December suicide of Huntington’s involuntary, of 16, Disorders Cognitive common fatal, Huntington’s 2014rare, 3excessive, among disease Symptoms genetic Disease patients patients neurological random Decline affected movements disorder Affects

  4. Slide 4: Huntington's Clinical Development Program

    Huntington’s Clinical Patients n8First-HD: ARC-HD Stable Overnight All Primary Phase 4Chorea 52 December Weeks =Week patients 453on (Placebo) score Registration Switch Development not endpoint: Treatment 4Long-term after tetrabenazine Switch: Rollover: switch Weeks 16, from onDisease evaluated Rollo

  5. Slide 5: First-HD: Key Selection Criteria and Patient Disposition

    Selection First-HD: –Key Efficacy nSD-809 Number Primary Adverse Physician December Active Total Subject Serious, Recent (%)Inclusion Exclusion nFunctional Maximal (%) Placebo Reason of Event suicidal analyses treatment Criteria has Decision untreated/undertreated 16, Randomized Subjects n reliable

  6. Slide 6: Positive Pre-Specified Treatment Effect

    Positive Pre-Specified Treatment Effect 2.5 Maintenance 37 Percent Points Improvement Change 4.0 Baseline 1TMC Placebo *Primary Dose 6December Percentage Points atPoints and Change Week in Topline toefficacy over TMC Total 16,2014 TMS Maintenance Therapy* 21 Improvement of Motor 12 16 SD-809 in Moto

  7. Slide 7: Met Pre-specified Key Secondary Endpoints

    Met Pre-specified 1. 2. 3. Life 214. December Analyzed Success Patient Clinical SF-36 Berg Multiple measure) Balance Physical Global defined 16,2014 Global using Key from Test Impression aFunctioning Impression as Secondary 7pre-specified Baseline much SD-809improved of to pEndpoints1 Endpoints ofSc

  8. Slide 8: Well-Tolerated Overall

    Well-Tolerated Overall similar No placebo reduction SD-809 >90% long-term Number nSystem Psychiatric Nervous All Cardiac Ear Eye General Gastrointestinal Hepatobiliary Infections Injury, Investigations Complications Musculoskeletal Tissue Renal Reproductive Breast Respiratory, Mediastinal Skin Disor

  9. Slide 9: Rates of Psychiatric and Nervous System Adverse Events

    Rates Psychiatric Number nSystem PSYCHIATRIC Depression/Agitated Abnormal Agitation Anxiety Suicidal Compulsions Impulsive Sleep NERVOUS Dizziness Akathisia/Restlessness Cognitive Drooling Dyskinesia Migraine Headache Loss Syncope December = 45of Disorder ofnOrgan Consciousness 1Adverse of Ideation

  10. Slide 10: Rates of General and Gastrointestinal Adverse Events

    Rates General Number nSystem GENERAL Fatigue Gait Chest Hangover GASTROINTESTINAL DISORDERS Constipation Nausea Abdominal Dyspepsia Frequent Gastrointestinal Vomiting Dysphagia Flatulence Salivary December = 45 Disturbance of Pain n1Organ 3and of Key = hypersecretion bowel (2.2%) 0(6.7%) 116, 45 010

  11. Slide 11: Cross-Study Comparison Table: First-HD and Xenazine

    Cross-Study Table First-HD XENAZINE Body Sedation/somnolence Insomnia Depression PSYCHIATRIC Appetite Obsessive Akathisia Balance CENTRAL NERVOUS Dysarthria Gait Headache GASTROINTESTINAL SYSTEM Fatigue BODY GENERAL Ecchymosis RESPIRATORY Bronchitis URINARY SD-809 -1235nDISORDERS S — This Note or De

  12. Slide 12: ARC-HD Long-Term Safety Study

    HD Patients First-HD: n8ARC-HD Stable Overnight All Primary Phase 4Chorea 52 December Weeks =Week patients 45 Clinical 3on (Placebo) score Registration Switch not endpoint: Treatment 4Long-term after Tetrabenazine Switch: Rollover: switch Weeks 16, from on Development evaluated Rollover 2014 tetrabe

  13. Slide 13: ARC-HD Switch: Chorea Score Change

    Chorea 37 of 13O N Baseline -3 (TBZ) Week reported December vernight ~41 =Tetrabenazine Patients 368mg (Weeks N Control during adverse 1= ~20 switch 16, 2on 35 3 2014 mg Stable 4on N long-The Maintained 5events Values =2SD-809 ~29 621 to 13 7Dose SD-809 8* Score mg in represent safety Therapy) ARC-H

  14. Slide 14: Three Drugs, Unmet Needs in Movement Disorders

    Three 100,000 Drugs Syndrome Tardive No Patients Estimated Huntington’ December Timedrugs Horizons have and Dyskinesia SUCCESS approved KEY 30,000 16, risk Tourette Tetrabenazine 2014 for DRIVERS ofPatients tardive Tardive Growth Children 14 Estimated dyskinesia 2013 OF in for Tourette the SD-809: F

  15. Slide 15: Anticipated Milestones

    Anticipated MILESTONES Huntington’s Disease First-HD: Not on ARC-HD Tardive Open-Label Dyskinesia AIM-TD, ARM-TD Double-Blind, AIM-TD Blind, Tourette Syndrome 8in IPF Fibrotic (S December Week Yale 560) Tetrabenazine, and onPlacebo-Controlled Tetrabenazine Global Treatment ARM-TD, Phase Other Condit

Auspex Pharmaceuticals — Investor Presentation (December 2014) on 6ix